Aquestive Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Aquestive Therapeutics generated cash of -$6,380,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,974,000 last year. Net change in cash is therefore -$3,401,000.
Cash Flow
| 2016 | -8.17M | 190K | 5.68M |
|---|---|---|---|
| 2017 | 5.82M | -2.06M | 4.41M |
| 2018 | -12.99M | -1.82M | 58.03M |
| 2019 | -60.21M | -663K | 49.6M |
| 2020 | -45.45M | -517K | 28.45M |
| 2021 | -32.97M | -913K | 30.10M |
| 2022 | -9.78M | -2.52M | 11.56M |
| 2023 | -6.38M | -995K | 3.97M |
AQST Cash Flow Statement (2016 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 27.27M | 28.02M | 31.80M | 49.32M | 60.59M | 17.37M | 9.20M | 11.50M |
Operating activities | ||||||||
Net income | -7.87M | -54.41M | -70.53M | -55.78M | -66.24M | -61.37M | -8.94M | -9.60M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||||
Depreciation and amortization | 1.34M | 2.38M | 2.96M | 3.44M | 2.90M | 3.23M | 3.80M | 3.89M |
Stock-based compensation expense | 2.68M | 4.38M | 6.81M | 6.58M | 7.07M | 0 | 0 | 0 |
| Deferred income tax benefit | 2.68M | 4.38M | 6.81M | 6.58M | 7.07M | 0 | 0 | 0 |
| Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | -3.07M | 7.35M | -4.93M | 1.20M | -7.43M | -409K | 4.69M | -6.50M |
Inventories | -989K | -1.74M | -1.57M | 398K | 2.58M | -1.42M | -1.12M | -1.58M |
Accounts payable | -1.02M | 1.63M | 1.22M | -5.18M | -7.87M | 11.31M | 2.94M | 1.65M |
Cash generated by operating activities | -6.38M | -9.78M | -32.97M | -45.45M | -60.21M | -12.99M | 5.82M | -8.17M |
Investing activities | ||||||||
Purchases Of Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -995K | -2.52M | -913K | -517K | -663K | -1.82M | -2.06M | -976K |
Acquisitions Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash generated by investing activities | -995K | -2.52M | -913K | -517K | -663K | -1.82M | -2.06M | 190K |
Financing activities | ||||||||
Common Stock Issued | 8.91M | 13.58M | 29.78M | 6.21M | 39.31M | 68.71M | 24K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | -14K | -99K | 0 | 0 | 0 | 0 |
Repayments of term debt | -20.38M | 0 | 0 | -24.75M | 17.05M | 0 | 5M | -38.06M |
Cash used in financing activities | 3.97M | 11.56M | 30.10M | 28.45M | 49.6M | 58.03M | 4.41M | 5.68M |
Net Change In Cash | -3.40M | -751K | -3.78M | -17.51M | -11.27M | 43.22M | 8.17M | -2.29M |
Cash at end of period | 23.87M | 27.27M | 28.02M | 31.80M | 49.32M | 60.59M | 17.37M | 9.20M |
| Data source | Data source | Data source | Data source | Data source | Data source |